Celcuity Inc. (CELC) News
Track canonical SquawkNews coverage tagged to CELC, Celcuity Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 24 indexed stories across 11 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Celcuity launches REVTORPYK commercially in US for HR+/HER2- advanced breast cancer
Celcuity announced REVTORPYK is now commercially available in the U.S. for eligible HR+/HER2- advanced breast cancer patients without a PIK3CA mutation.Key Highlights:Original SEC Filing: Celcuity Inc. [ CELC ] - 8-K - S
REGULATION | Sep 30, 2026, 12:13 PM UTC
L
Celcuity Inc. (CELC) Launches REVTORPYK Commercially in U.S.
Celcuity said REVTORPYK (gedatolisib) is now commercially available in the U.S. for HR+/HER2- advanced breast cancer without a PIK3CA mutation, in combo with fulvestrant with or without palbociclib, following progression
NEWS | Sep 30, 2026, 12:09 PM UTC
L
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
REVTORPYK (gedatolisib)MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. NASDAQ:CELC, a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid t
NEWS | Sep 30, 2026, 12:09 PM UTC
M
CELC launches REVTORPYK for HR-positive, HER2-negative advanced breast cancer
Celcuity (CELC) says REVTORPYK is launching for HR-positive, HER2-negative advanced breast cancer, with broad physician awareness and market-access groundwork. Phase III studies are ongoing, and expanded manufacturing is
EQUITY | Sep 09, 2026, 01:26 PM UTC
M
Celcuity launches REVTORPYK for HR-positive, HER2-negative advanced breast cancer
Celcuity Inc is launching REVTORPYK for HR-positive, HER2-negative advanced breast cancer, with broad clinical development in breast and prostate cancer. Expanded manufacturing is planned, alongside subcutaneous formulat
EQUITY | Sep 09, 2026, 12:56 PM UTC
M
CELC’s REVTORPYK gains approval; second-line breast cancer launch planned this quarter
REVTORPYK has received approval for second-line metastatic breast cancer. Commercial launch is planned this quarter, and a supplemental NDA for PIK3CA-mutant patients is under review, supported by strong clinical data an
EQUITY | Sep 08, 2026, 03:51 PM UTC
M
CELC gets approval; commercial launch planned this quarter
REVTORPYK was approved for second-line metastatic breast cancer. A commercial launch is planned for this quarter, while a supplemental NDA for PIK3CA-mutant patients is under review.
EQUITY | Sep 08, 2026, 03:09 PM UTC
L
Celcuity to participate in upcoming investor conferences
Celcuity Inc. announced that CEO and co-founder Brian Sullivan will participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
CELC - Celcuity To Participate in Upcoming Investor Conferences
CELC - Celcuity To Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 12:31 PM UTC
L
Celcuity submits sNDA for REVTORPYK after positive VIKTORIA-1 results
Celcuity has submitted an sNDA for REVTORPYK following positive VIKTORIA-1 PIK3CA mutant results.
EQUITY | Aug 26, 2026, 12:43 PM UTC
M
Celcuity submits sNDA to FDA for REVTORPYK in HR+/HER2-, PIK3CA-mutant breast cancer
Celcuity submitted an sNDA to the FDA for REVTORPYK (gedatolisib) for HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer.
REGULATION | Aug 26, 2026, 12:30 PM UTC
L
Celcuity Inc. releases Q2 2026 financial results and corporate update
Celcuity Inc. (CELC) reports the release of its second quarter 2026 financial results and provides a corporate update.
EARNINGS | Aug 13, 2026, 08:06 PM UTC
L
CELC - Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
CELC - Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
EARNINGS | Aug 06, 2026, 12:34 PM UTC
L
CELC - Newly FDA -Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guideli
CELC - Newly FDA -Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
REGULATION | Jul 30, 2026, 12:31 PM UTC
L
Short Report: Bears book profits in Celcuity
Welcome to this week's installment of "The Short Interest Report" - weekly recap of short interest trends among some of the most widely followed high-short-float stocks. Using the data from our partner Ortex.com, which u
EQUITY | Jul 26, 2026, 02:48 PM UTC
L
CELC PIK3CA-WT Finds its Drug; Celcuity Enters Commercial Lane; New PT $155; Reiterate Buy @ HCW
CELC PIK3CA-WT Finds its Drug; Celcuity Enters Commercial Lane; New PT $155; Reiterate Buy @ HCW
EQUITY | Jul 15, 2026, 12:57 PM UTC
L
CELC shares fall premarket after rising late Tuesday when the FDA approved its drug for an advanced form of breast cancer, making it the com
CELC shares fall premarket after rising late Tuesday when the FDA approved its drug for an advanced form of breast cancer, making it the company's first product to gain market entry… but the company delayed the launch un
REGULATION | Jul 15, 2026, 11:49 AM UTC
L
CELC -7% pre mtk after FDA headlines late yesterday
CELC -7% pre mtk after FDA headlines late yesterday
REGULATION | Jul 15, 2026, 11:45 AM UTC
L
CELC Maintain Market Outperform, raise PT to $177 (from $160) following FDA approval @ Citizens
CELC Maintain Market Outperform, raise PT to $177 (from $160) following FDA approval @ Citizens
REGULATION | Jul 15, 2026, 11:23 AM UTC
L
Celcuity's REVTORPYK Gets FDA Approval for HR+/HER2- Breast Cancer
() -- Celcuity (CELC) said Tuesday the US Food and Drugs Administration approved REVTORPYK for treating patients with hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA
REGULATION | Jul 14, 2026, 09:19 PM UTC
L
CELC -7% in AHs trading - PR on earlier FDA news: Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2
CELC -7% in AHs trading - PR on earlier FDA news: Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer -REVTORPYK is th
REGULATION | Jul 14, 2026, 08:56 PM UTC
L
CELC shares popping on the FDA approval, up 7.2% last
CELC shares popping on the FDA approval, up 7.2% last
REGULATION | Jul 14, 2026, 07:27 PM UTC
L
CELC FDA: approves gedatolisib with fulvestrant, with or without palbociclib, for hr-positive, her2-negative locally advanced or metastatic
CELC FDA: approves gedatolisib with fulvestrant, with or without palbociclib, for hr-positive, her2-negative locally advanced or metastatic breast cancer
REGULATION | Jul 14, 2026, 07:20 PM UTC
L
FDA approves Celcuity's gedatolisib combo for certain breast cancers
The Food and Drug...
REGULATION | Jul 14, 2026, 07:16 PM UTC